Investor Relations
MAP Pharmaceuticals is an innovative drug company focused on providing better treatments for patients with neurological diseases. Taking an integrated scientific approach, MAP Pharmaceuticals seeks to place better care into patients' hands by enhancing how proven drugs perform, through targeted dosing regimens and novel delivery systems. MAP Pharmaceuticals' goal is to develop treatments that provide patients with greater control, improved efficacy and fewer side effects.
Recent Releases
May 4, 2012
MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
May 1, 2012
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 12, 2012
MAP Pharmaceuticals Provides Update on LEVADEX® Program
